Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring
Recommended Citation
Choi WJ, Ivanics T, Gravely A, Gallinger S, Sapisochin G, and O'Kane GM. Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring. Ann Surg Oncol 2023.
Document Type
Article
Publication Date
2-20-2023
Publication Title
Annals of surgical oncology
Abstract
In this review, we present the current evidence and future perspectives on the use of circulating tumour DNA (ctDNA) in the diagnosis, management and understanding the prognosis of patients with intrahepatic cholangiocarcinoma (iCCA) undergoing surgery. Liquid biopsies or ctDNA maybe utilized to: (1) determine the molecular profile of the tumour and therefore guide the selection of molecular targeted therapy in the neoadjuvant setting, (2) form a surveillance tool for the detection of minimal residual disease or cancer recurrence after surgery, and (3) diagnose and screen for early iCCA detection in high-risk populations. The potential for ctDNA can be tumour-informed or -uninformed depending on the goals of its use. Future studies will require ctDNA extraction technique validations, with standardizations of both the platforms and the timing of ctDNA collections.
Medical Subject Headings
Humans; Circulating Tumor DNA/genetics; Neoplasm; Residual/diagnosis/surgery; Neoplasm Recurrence; Local/diagnosis/genetics; Cholangiocarcinoma/diagnosis/genetics/surgery; Bile Duct Neoplasms/diagnosis/genetics/surgery; Bile Ducts; Intrahepatic; Biomarkers; Tumor/genetics
PubMed ID
36808320
ePublication
ePub ahead of print
Volume
30
Issue
6
First Page
3849
Last Page
3863
